Thomas K Equels - 06 Mar 2026 Form 4 Insider Report for AIM ImmunoTech Inc. (AIM)

Role: CEO & President
Signature: /s/ Thomas K Equels
Issuer symbol: AIM
Transactions as of: 06 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 10 Mar 2026, 17:56:40 UTC
Previous filing: 13 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Equels Thomas K	CEO & President	2117 SOUTHWEST HIGHWAY 484, OCALA,	/s/ Thomas K Equels	10 Mar 2026	0001450324

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AIM	Common Stock						38,922	06 Mar 2026	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AIM	Series G Convertible Preferred Stock	Other		+25		$25000.00^*	25	06 Mar 2026	Series G Convertible Preferred Stock	25	$1000.00	Direct	F1, F2
transaction	AIM	Class G Warrants	Other		+50,000		$0.000000^*	50,000	06 Mar 2026	Common Stock	50,000	$1.00	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share has a stated value of $1,000 and is convertible into 1,000 shares of common stock and was issued as part of a subscription right issued in a rights offering.
F2	n/a - Preferred shares are perpetual.
F3	Each warrant is exercisable for one share of common stock at an exercise price of $1.00 per share and was issued as part of a subscription right issued in a rights offering.